The association of polypharmacy with COVID-19 outcomes independent of comorbidities in people with type 2 diabetes: implications for the unforeseen consequences of polypharmacy

Cardiovasc Endocrinol Metab. 2024 May 23;13(2):e0304. doi: 10.1097/XCE.0000000000000304. eCollection 2024 Jun.

Juhi K Gupta¹, Rathi Ravindrarajah¹, George Tilston¹, Wiliam Ollier², Darren M Ashcroft^{3

4}, Adrian H Heald^{5

6}

¹ Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester.
² Faculty of Science and Engineering, Manchester Metropolitan University.
³ Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester.
⁴ NIHR Greater Manchester Patient Safety Research Collaboration (PSRC), University of Manchester, Manchester.
⁵ Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford and.
⁶ Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

No abstract available